506 related articles for article (PubMed ID: 26808918)
1. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
2. Targeting cancer-derived adenosine: new therapeutic approaches.
Young A; Mittal D; Stagg J; Smyth MJ
Cancer Discov; 2014 Aug; 4(8):879-88. PubMed ID: 25035124
[TBL] [Abstract][Full Text] [Related]
3. Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses.
Young A; Ngiow SF; Barkauskas DS; Sult E; Hay C; Blake SJ; Huang Q; Liu J; Takeda K; Teng MWL; Sachsenmeier K; Smyth MJ
Cancer Cell; 2016 Sep; 30(3):391-403. PubMed ID: 27622332
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
5. CD73: an emerging checkpoint for cancer immunotherapy.
Chen S; Wainwright DA; Wu JD; Wan Y; Matei DE; Zhang Y; Zhang B
Immunotherapy; 2019 Aug; 11(11):983-997. PubMed ID: 31223045
[TBL] [Abstract][Full Text] [Related]
6. Increased efficacy of a dendritic cell-based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor.
Arab S; Kheshtchin N; Ajami M; Ashurpoor M; Safvati A; Namdar A; Mirzaei R; Mousavi Niri N; Jadidi-Niaragh F; Ghahremani MH; Hadjati J
Tumour Biol; 2017 Mar; 39(3):1010428317695021. PubMed ID: 28349824
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive activities of adenosine in cancer.
Allard B; Beavis PA; Darcy PK; Stagg J
Curr Opin Pharmacol; 2016 Aug; 29():7-16. PubMed ID: 27209048
[TBL] [Abstract][Full Text] [Related]
8. Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A
Varano F; Catarzi D; Vincenzi F; Pasquini S; Pelletier J; Lopes Rangel Fietto J; Espindola Gelsleichter N; Sarlandie M; Guilbaud A; Sévigny J; Varani K; Colotta V
Bioorg Med Chem Lett; 2020 May; 30(9):127067. PubMed ID: 32165041
[TBL] [Abstract][Full Text] [Related]
9. CD73 as a potential opportunity for cancer immunotherapy.
Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
[TBL] [Abstract][Full Text] [Related]
10. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
11. Oxygenation and A2AR blockade to eliminate hypoxia/HIF-1α-adenosinergic immunosuppressive axis and improve cancer immunotherapy.
Halpin-Veszeleiova K; Hatfield SM
Curr Opin Pharmacol; 2020 Aug; 53():84-90. PubMed ID: 32841869
[TBL] [Abstract][Full Text] [Related]
12. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors.
Beavis PA; Divisekera U; Paget C; Chow MT; John LB; Devaud C; Dwyer K; Stagg J; Smyth MJ; Darcy PK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):14711-6. PubMed ID: 23964122
[TBL] [Abstract][Full Text] [Related]
13. Targeting the CD73-adenosine axis in immuno-oncology.
Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
[TBL] [Abstract][Full Text] [Related]
14. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Allard B; Cousineau I; Spring K; Stagg J
Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245
[TBL] [Abstract][Full Text] [Related]
15. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
16. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression.
Jin D; Fan J; Wang L; Thompson LF; Liu A; Daniel BJ; Shin T; Curiel TJ; Zhang B
Cancer Res; 2010 Mar; 70(6):2245-55. PubMed ID: 20179192
[TBL] [Abstract][Full Text] [Related]
17. Targeting the adenosine pathway for cancer immunotherapy.
Hammami A; Allard D; Allard B; Stagg J
Semin Immunol; 2019 Apr; 42():101304. PubMed ID: 31604539
[TBL] [Abstract][Full Text] [Related]
18. [A new generation of immunotherapies targeting the CD39/CD73/adenosine pathway to promote the anti-tumor immune response].
Gros L; Paturel C; Perrot I; Bensussan A; Eliaou JF; Bastid J; Bonnefoy N
Med Sci (Paris); 2020 Feb; 36(2):112-115. PubMed ID: 32129745
[No Abstract] [Full Text] [Related]
19. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
20. Complex regulation of ecto-5'-nucleotidase/CD73 and A
Nedeljkovic N
Pharmacol Res; 2019 Jun; 144():99-115. PubMed ID: 30954629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]